MYGN

Conviction 18HealthcareScan · Thu, Sep 24, 2026

Myriad Genetics Inc (MYGN) closed at $4.16 (+3.62%) on Sep 24, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 65, RS Rating 10, -49.2% from its 52-week high, -32.3% year to date. Sector: Healthcare · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

MYGN$4.16+3.62%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 2.37M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

MYRIAD GENETICS INCIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.myriad.com ↗

Price4.16

Change+3.62%

Gap-1.25%

Rel volume0.98×

Avg volume2.14M

Avg $ vol7.81M

SMA 203.56

SMA 503.86

SMA 2004.84

Price vs 50+7.60%

Price vs 200-14.10%

MA stackmixed

50/200 cross—

Supertrendup · 3.33

RSI (14)65

MACD hist0.11

MACD cross—

Stoch %K / %D92 / 87

ADX (14)33

+DI / −DI25 / 12

RSI divergence—

MACD divergence—

ATR %6.19%

ADR %6.57%

52w high8.18

52w low2.86

From 52w high-49.21%

Above 52w low+45.28%

New 52w highNo

SqueezeOff

Bollinger width42.88%

%B0.89

Donchian pos92.86%

Donchian high4.25

Donchian low2.92

AVWAP (52w high)4.80

vs AVWAP high-13.44%

AVWAP (52w low)3.37

vs AVWAP low+23.40%

OBV trendUp

Chaikin MF (20)0.38

Today vs 20d0.98×

Avg vol (14d)2.37M

Avg vol (20d)2.14M

Avg $ vol (20d)7.81M

Market cap397.42M

RS Rating10 / 99

RS 3m (vs SPY)-27.97%

RS 6m (vs SPY)-28.04%

RS line new highNo

Trend template2/8

Technical rank50.9

1 week+0.36%

1 month+30.25%

3 months-23.48%

6 months-11.22%

1 year-46.04%

YTD-32.33%

P/E-1.09

P/B1.31

P/S0.48

P/FCF-9.14

EPS-3.95

Div yield—

ROE-120.40%

ROA-57.27%

Debt/Eq0.59

Current2.21

EV/EBITDA-1.22

Gross margin69.93%

Net margin-44.38%

Rev growth-1.56%

EPS growth-187.43%

Price target3.04

Target upside-26.84%

Analyst ratingHold

Institutional103.05%

Ent. value462.32M

Revenue190.7M

Net income-43.2M

Gross profit127M

Free cash flow-43.5M

IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

ExchangeNasdaq

Shares out94.45M

Employees2.7K

ListedFri, Oct 6, 1995

Free float89.75M

Float %96.0%

Short interest7.84M

Days to cover5.0d

Short volume39.0%

Squeeze score42 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.33 vs −$0.08

Last surprise-312.5% miss

Setup gradeD

Conviction18 / 100

Pattern quality—

Tech rank50.9 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance4.17

Support2.79

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

Setting up
Jul 13 – Sep 9
3 scans
→
Breaking out now
Sep 10
1 scan
→
Broke out
Sep 11 – Sep 18
6 scans

Congress activity

Disclosed STOCK Act trades in MYGN

All disclosures →

No recent disclosed trades by Congress in MYGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MYGN · open-market 1 sell

Insider	Side	Shares	Value	Traded	Filed
Sikri Vishal EVP, Commercial · Common Stock · 2026-09-16	Grant	257.73K	—	2026-09-16	2026-09-17
Wheeler Benjamin Richard Chief Financial Officer · Common Stock · 2026-08-16	Tax	8.76K	$27K	2026-08-16	2026-08-17
Kumar Rashmi Director · Common Stock · 2026-06-08	Sell	15K	$67K	2026-06-08	2026-06-09
Dreismann Heinrich Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Bisaro Paul Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Newcomer Lee Nisley Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Davis Mark Steven Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Phanstiel S. Louise Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Kumar Rashmi Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05
Reitan Colleen F Director · Common Stock · 2026-06-04	Grant	59.7K	$0	2026-06-04	2026-06-05

SEC filings

EDGAR filings in MYGN · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.